← Back to Clinical Trials
Recruiting NCT07213245

NCT07213245 Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07213245
Status Recruiting
Phase
Sponsor Göteborg University
Condition Appetite
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2025-12-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Meal high in energy density, high in ultra-processed foodMeal high in energy density, low in ultra-processed foodMeal low in energy density, high in ultra-processed food

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2025-12-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall aim of this project is to study the effects of short-term high ultra-processed food intake, compared to nutrient- and energy density matched low ultra-processed food (UPF) intake, on energy intake and appetite. A total of 24 men and women who meet all inclusion criteria and none of the exclusion criteria will be invited to participate. A randomized 2\*2 factorial four-way crossover study will be conducted at the Department of Internal medicine and Clinical Nutrition at the University of Gothenburg, comparing a high-UPF meal to a low-UPF meal also with high and/or low energy density. A supervised breakfast meal will be served, and postprandial blood samples and appetite measures will be collected continuously up to 4 hours after the breakfast meal. Subsequently, an ad libitum lunch meal will be served, and energy intake will be recorded.

Eligibility Criteria

Inclusion Criteria: * Body mass index (BMI) 18.5-30 kg/m2 * Fasting glucose \< 6.1 mmol/l * Hb \>110 g/L * Weight stability the last 3 months +/-5% Exclusion Criteria: * Food allergies, intolerances or preferences preventing consumption of any products included in the study. * Unable to sufficiently understand written and spoken Swedish or English to provide written consent and understand information and instructions from the study personal. * Pregnant, lactating or planning a pregnancy during the study period. * Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study. * History of gastrointestinal conditions or major gastrointestinal surgery (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.). * Type 1 diabetes or type 2 diabetes. * Thyroid disorder. * Current smoking, vaping. * Following any weight reduction program or having followed one during the last 6 months prior to screening. * Not habitually eating breakfast (\<5 times/week). * Restrained eating based on the three-factor eating questionnaire.

Contact & Investigator

Central Contact

Therese Karlsson, PhD

✉ therese.karlsson@gu.se

📞 +46704089150

Principal Investigator

Therese Karlsson, PhD

PRINCIPAL INVESTIGATOR

University of Gothenburg, Institute of medicine

Frequently Asked Questions

Who can join the NCT07213245 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Appetite. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07213245 currently recruiting?

Yes, NCT07213245 is actively recruiting participants. Contact the research team at therese.karlsson@gu.se for enrollment information.

Where is the NCT07213245 trial being conducted?

This trial is being conducted at Gothenburg, Sweden.

Who is sponsoring the NCT07213245 clinical trial?

NCT07213245 is sponsored by Göteborg University. The principal investigator is Therese Karlsson, PhD at University of Gothenburg, Institute of medicine. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology